"Not one of Australia’s ASX-listed cannabinoid-focused companies has produced a full-year profit since cannabis cultivation was legalised in 2016, despite talk of multi-billion dollar opportunities to treat conditions from sleep apnoea to inflammatory bowel disease and concussion."
